An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Drug penetration in solid tumours

Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,058

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771

Small-scale systems for in vivo drug delivery

LaVan, D. A., McGuire, T., & Langer, R. (2003) · Nature Biotechnology · doi:10.1038/nbt876 · Cited by 1,314

Sequence analysis of mutations and translocations across breast cancer subtypes

Banerji, S. O., Cibulskis, K., Rangel‐Escareño, C., Brown, K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A., Sougnez, C. L., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,181

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070

The productivity crisis in pharmaceutical R&D

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918

A view on drug resistance in cancer

Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817

Emerging Frontiers in Drug Delivery

Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 1,009

Personalized medicine: motivation, challenges, and progress

Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976

A new chapter in pharmaceutical manufacturing: 3D-printed drug products

Norman, J. J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.001 · Cited by 832

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642

Precision medicine for cancer with next-generation functional diagnostics

Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570

Enabling Technologies for Personalized and Precision Medicine

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517

Functional precision cancer medicine—moving beyond pure genomics

Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors

Davidson, S. M., Jonas, O., Keibler, M. A., Hou, H. W., Luengo, A., Mayers, J. R., Wyckoff, J., Del Rosario, A. M., Whitman, M., Chin, C. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4256 · Cited by 331

Independent Drug Action in Combination Therapy: Implications for Precision Oncology

Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 338

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282

Engineering and physical sciences in oncology: challenges and opportunities

Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273

Biopolymers for Antitumor Implantable Drug Delivery Systems: Recent Advances and Future Outlook

Talebian, S., Foroughi, J., Wade, S. J., Vine, K. L., Dolatshahi‐Pirouz, A., Mehrali, M., Conde, J., & Wallace, G. G. (2018) · Advanced Materials · doi:10.1002/adma.201706665 · Cited by 226

Engineering precision biomaterials for personalized medicine

Aguado, B. A., Grim, J. C., Rosales, A. M., Watson-Capps, J. J., & Anseth, K. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8645 · Cited by 216

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 212

Tumor Cell–Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression

Oudin, M. J., Jonas, O. H., Kosciuk, T., Broye, L. C., Guido, B. C., Wyckoff, J., Riquelme, D. N., Lamar, J. M., Asokan, S. B., Whittaker, C. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1183 · Cited by 207

Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and MetastasisPreprint

Oudin, M. J., & Weaver, V. M. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030817 · Cited by 194

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194

The impact of tumour pH on cancer progression: strategies for clinical intervention

Ward, C., Meehan, J., Gray, M., Murray, A. F., Argyle, D. J., Kunkler, I. H., & Langdon, S. P. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00005 · Cited by 180

Implantable biosensors and their contribution to the future of precision medicine

Gray, M., Meehan, J., Ward, C., Langdon, S. P., Kunkler, I. H., Murray, A., & Argyle, D. J. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.07.011 · Cited by 173

Design and fabrication of drug‐delivery systems toward adjustable release profiles for personalized treatment

Geraili, A., Xing, M. M. Q., & Mequanint, K. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200126 · Cited by 165

Molecular Diagnostics in Clinical Oncology

Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 151

Solid implantable devices for sustained drug delivery

Magill, E., Demartis, S., Gavini, E., Permana, A. D., Thakur, R. R. S., Adrianto, M. F., Waite, D. T., Glover, K., Picco, C. J., Korelidou, A., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114950 · Cited by 152

Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer

Hu, C. T., Liu, X., Ran, W., Meng, J., Zhai, Y., Zhang, P., Yin, Q., Yu, H., Zhang, Z., & Li, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.009 · Cited by 144

A flexible electronic strain sensor for the real-time monitoring of tumor regression

Abramson, A., Chan, C. T., Khan, Y., Mermin-Bunnell, A. M., Matsuhisa, N., Fong, R., Shad, R., Hiesinger, W., Mallick, P., Gambhir, S. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6550 · Cited by 124

Microneedle-based delivery devices for cancer therapy: A review

Moreira, A. F., Rodrigues, C. F., Jacinto, T. A., Miguel, S. P., Costa, E. C., & Correia, I. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104438 · Cited by 126

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3697 · Cited by 106

Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Wong, A. H., Li, H., Jia, Y., Mak, P., Martins, R. P., Liu, Y., Vong, C., Wong, H. C., Wong, P. K., Wang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08831-z · Cited by 105

Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy

Pan, S., Zhang, Y., Natalia, A., Lim, C. Z. J., Ho, N. R. Y., Chowbay, B., Loh, T. P., Tam, J. K. C., & Shao, H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00872-w · Cited by 103

Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications

Cicha, I., Priefer, R., Severino, P. B., Souto, E. B., & Jain, S. A. (2022) · Biomolecules · doi:10.3390/biom12091198 · Cited by 102

Phase 0/microdosing approaches: time for mainstream application in drug development?

Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 109

Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems

van Elk, M., Murphy, B. P., Eufrásio-da-Silva, T., O’Reilly, D. P., Vermonden, T., Hennink, W. E., Duffy, G. P., & Ruiz‐Hernández, E. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.013 · Cited by 100

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

Watson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Villarruel, L. A., Scilletta, N. A., Bellino, M. G., Desimone, M. F., & Catalano, P. N. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00827 · Cited by 89

Multiplexed drug testing of tumor slices using a microfluidic platform

Horowitz, L. F., Rodriguez, A. D., Dereli-Korkut, Z., Lin, R., Castro, K., Mikheev, A. M., Monnat, R. J., Folch, A., & Rostomily, R. C. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0117-y · Cited by 88

Emerging Technologies for Local Cancer Treatment

Chua, C. Y. X., Ho, J., Demaria, S., Mauro Ferrari, B., & Grattoni, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000027 · Cited by 88

Bioinspired Hydrogels to Engineer Cancer Microenvironments

Park, K. M., Lewis, D. M., & Gerecht, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044619 · Cited by 85

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions

Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84

Patient-derived xenografts (PDXs) as model systems for human cancer

Invrea, F., Rovito, R., Torchiaro, E., Petti, C., Isella, C., & Médico, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.003 · Cited by 79

A microfluidic platform for functional testing of cancer drugs on intact tumor slices

Rodriguez, A. D., Horowitz, L. F., Castro, K., Kenerson, H., Bhattacharjee, N., Gandhe, G., Raman, A., Monnat, R. J., Yeung, R., Rostomily, R. C., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc00811j · Cited by 77

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 72

Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning

Ahuja, K., Rather, G. M., Lin, Z., Sui, J., Xie, P., Le, T. D., Bertino, J. R., & Javanmard, M. (2019) · Microsystems & Nanoengineering · doi:10.1038/s41378-019-0073-2 · Cited by 73

Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy

Alimardani, V., Abolmaali, S. S., Tamaddon, A. M., & Ashfaq, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00819-z · Cited by 70

An in vivo multiplexed small-molecule screening platform

Grüner, B. M., Schulze, C. J., Yang, D., Ogasawara, D., Dix, M. M., Rogers, Z. N., Chuang, C.-H., McFarland, C. D., Chiou, S.-H., Brown, J. M., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3992 · Cited by 62

Microdissected “cuboids” for microfluidic drug testing of intact tissues

Horowitz, L. F., Rodriguez, A. D., Au-Yeung, A., Bishop, K. W., Barner, L. A., Mishra, G., Raman, A., Delgado, P., Liu, J. T. C., Gujral, T. S., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc00801j · Cited by 62

Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems

Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 61

You Put What, Where?

Heffernan, K. J., Vetere, F., & Chang, S. (2016) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/2858036.2858392 · Cited by 58

Microfluidic technologies for wearable and implantable biomedical devices

Wang, Z., Shah, A., Lee, H., & Lee, C. H. (2025) · Lab on a Chip · doi:10.1039/d5lc00499c · Cited by 62

Communication protocols integrating wearables, ingestibles, and implantables for closed-loop therapies

Ghanim, R. W., Kaushik, A., Park, J., & Abramson, A. (2023) · Device · doi:10.1016/j.device.2023.100092 · Cited by 57

Integrated genetic and pharmacologic interrogation of rare cancers

Hong, A. L., Tseng, Y., Cowley, G. S., Jonas, O. H., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11987 · Cited by 54

REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks

Chatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 55

Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues

Slika, H., Karimov, Z., Alimonti, P., Abou‐Mrad, T., Fazio, E. D., Alomari, S., & Tyler, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216316 · Cited by 52

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. S., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01379-y · Cited by 52

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers

Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 47

Tissue-Agnostic Drug Development

Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 47

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development

Jonas, O. H., Calligaris, D., Methuku, K. R., Poe, M. M., Francois, J. P., Tranghese, F., Changelian, A. N., Sieghart, W., Ernst, M. C., Krummel, D. P., et al. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2262 · Cited by 45

The Potential of Cryptophyte Algae in Biomedical and Pharmaceutical Applications

Abidizadegan, M., Peltomaa, E., & Blomster, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618836 · Cited by 47

Chemical Monitoring in Clinical Settings: Recent Developments toward Real-Time Chemical Monitoring of Patients

Booth, M. A., Gowers, S. A. N., Leong, C. L., Rogers, M. L., Samper, I. C., Wickham, A. P., & Boutelle, M. G. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04224 · Cited by 44

Microfluidics in Malignant Glioma Research and Precision Medicine

Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 46

Microfluidics for interrogating live intact tissues

Horowitz, L. F., Rodriguez, A. D., Ray, T. R., & Folch, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-0164-0 · Cited by 43

The past, present, and future of chemotherapy with a focus on individualization of drug dosing

DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42

An Implantable Micro-Caged Device for Direct Local Delivery of Agents

Son, A. I., Opfermann, J. D., McCue, C., Ziobro, J. M., Abrahams, J. H., Jones, K., Morton, P. D., Ishii, S., Oluigbo, C. O., Krieger, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17912-y · Cited by 43

Covalent organic frameworks (COFs) as carrier for improved drug delivery and biosensing applications

Younas, R., Jubeen, F., Bano, N., Andreescu, S., Hong-xia, Z., & Hayat, A. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28718 · Cited by 40

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Sant, G. R., Knopf, K., & Albala, D. M. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0025-y · Cited by 36

Drug delivery across length scales

Delcassian, D., Patel, A. K., Cortinas, A. B., & Langer, R. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1438440 · Cited by 39

Advanced Devices for Tumor Diagnosis and Therapy

Wang, L., Dai, C., Jiang, L., Tong, G., Xiong, Y., Khan, K., Tang, Z., Chen, X., & Zeng, H. (2021) · Small · doi:10.1002/smll.202100003 · Cited by 36

Made-on-demand, complex and personalized 3D-printed drug products

Osouli-Bostanabad, K., & Adibkia, K. (2018) · Bioimpacts · doi:10.15171/bi.2018.09 · Cited by 35

Therapeutic potential of microbial modulation in pancreatic cancer

Chandra, V., & McAllister, F. M. (2021) · Gut · doi:10.1136/gutjnl-2019-319807 · Cited by 35

Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro‐in vivo correlation

Vogus, D. R., Pusuluri, A., Chen, R., & Mitragotri, S. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10082 · Cited by 34

VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells

Patterson, J. C., Joughin, B. A., Prota, A. E., Mühlethaler, T., Jonas, O. H., Whitman, M. A., Varmeh, S., Chen, S., Balk, S. P., Steinmetz, M. O., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.009 · Cited by 29

Flexible Transient Bioelectronic System Enables Multifunctional Active‐Controlled Drug Delivery

Liu, S., Jia, Z., Yang, F., Ning, T., Gu, X., Niu, X., & Fan, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202215034 · Cited by 28

Synergistic interactions with PI3K inhibition that induce apoptosis

Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28

Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform

Nguyen, T. N. H., Horowitz, L. F., Krilov, T., Lockhart, E. J., Kenerson, H. L., Gujral, T. S., Yeung, R. S. W., Arroyo‐Currás, N., & Folch, A. (2024) · Science Advances · doi:10.1126/sciadv.adn5875 · Cited by 27

Engineered miniaturized models of musculoskeletal diseases

Bersini, S., Arrigoni, C., Lopa, S., Bongio, M., Martín, I., & Moretti, M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.015 · Cited by 27

Biocompatibility of common implantable sensor materials in a tumor xenograft model

Gray, M., Meehan, J., Blair, E. O., Ward, C., Langdon, S. P., Morrison, L. R., Marland, J. R. K., Tsiamis, A., Kunkler, I. H., Murray, A., et al. (2018) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34254 · Cited by 25

Implantable Biomaterials for Cancer Immunotherapies

Печникова, Н. А., Aggeli, A., Latypova, A., Iaremenko, A. V., Domvri, K., Zubarev, I. V., Chuang, L. I. U., & Yaremenko, A. V. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202416813 · Cited by 26

Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas

Peruzzi, P., Dominas, C. A., Fell, G. G., Bernstock, J. D., Blitz, S. E., Mazzetti, D., Zdioruk, M. I., Dawood, H. Y., Triggs, D., Ahn, S. W., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0069 · Cited by 24

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

Patterson, J. C., Varkaris, A. S., Croucher, P. J. P., Ridinger, M., Dalrymple, S. L., Nouri, M., Xie, F., Varmeh, S., Jonas, O. H., Whitman, M. A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1533 · Cited by 24

Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models

Flobak, Å., Skånland, S. S., Hovig, E. J., Taskén, K., & Russnes, H. G. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.08.009 · Cited by 26

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities

Jonas, O. H., Oudin, M. J., Kosciuk, T., Whitman, M. A., Gertler, F. B., Cima, M. J., Flaherty, K. T., & Langer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2722 · Cited by 21

Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer

Gazdar, A. F., & Minna, J. D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw119 · Cited by 21

Engineering Heterogeneous Tumor Models for Biomedical Applications

Wu, Z., Huang, D., Wang, J., Zhao, Y., Sun, W., & Shen, X. (2023) · Advanced Science · doi:10.1002/advs.202304160 · Cited by 19

Taxol reduces synergistic, mechanobiological invasiveness of metastatic cells

Merkher, Y., Alvarez‐Elizondo, M. B., & Weihs, D. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa8c0b · Cited by 18

Drug testing in the patient: Toward personalized cancer treatment

Coombes, R. C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1214 · Cited by 17

The prospects of tumor chemosensitivity testing at the single-cell level

Yang, C., Yang, C., Yarden, Y., To, K. K. W., & Fu, L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100741 · Cited by 16

Bio-Internet of Things Through Micro-Circulation Network: A Molecular Communication Channel Modeling

Yue, G., Liu, Q., & Yang, K. (2024) · IEEE Internet of Things Journal · doi:10.1109/jiot.2024.3411048 · Cited by 17

In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy

Jonas, O. H., Kang, J. W., Singh, S. P., Lammers, A., Nguyen, F. T., Dasari, R. R., So, P. T. C., Langer, R., & Cima, M. J. (2018) · The Analyst · doi:10.1039/c8an00913a · Cited by 17

Understanding and embracing the complexities of the molecular communication channel in liquids

Wang, J., Hu, D., Shetty, C., & Hassanieh, H. (2020) · ACM Annual International Conference on Mobile Computing and Networking (MobiCom) · doi:10.1145/3372224.3419191 · Cited by 17

A Miniaturized Imaging Window to Quantify Intravital Tissue Regeneration within a 3D Microscaffold in Longitudinal Studies

Conci, C., Jacchetti, E., Sironi, L., Gentili, L., Cerullo, G., Osellame, R., Chirico, G. G., & Raimondi, M. T. (2022) · Advanced Optical Materials · doi:10.1002/adom.202101103 · Cited by 18

Overview of DNA repair pathways, current targets, and clinical trials bench to clinic

Kelley, M. R., & Fishel, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00001-2 · Cited by 18

Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma

Gundle, K. R., Deutsch, G. B., Goodman, H. J., Pollack, S. M., Thompson, M. J., Davis, J. L., Lee, M.-Y., Ramirez, D. C., Kerwin, W. S., Bertout, J. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0614 · Cited by 17

Strategies for Testing Intervention Matching Schemes in Cancer

Schork, N. J., Goetz, L. H., Lowey, J., & Trent, J. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1947 · Cited by 16

Strategic, feasibility, economic, and cultural aspects of phase 0 approaches

Burt, T., Roffel, A. F., Langer, O., Anderson, K., & DiMasi, J. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13269 · Cited by 15

Technological and computational advances driving high-throughput oncology

Kolmar, L., Autour, A., Ma, X., Vergier, B., Eduati, F., & Merten, C. A. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.04.008 · Cited by 16

Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions

Pal, K., & Sheth, R. A. (2022) · Cancers · doi:10.3390/cancers15010196 · Cited by 16

Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics

Tognon, C. E., Sears, R. C., Mills, G. B., Gray, J. W., & Tyner, J. W. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-043020-125955 · Cited by 15

A Miniaturized Platform for Multiplexed Drug Response Imaging in Live Tumors

Bhagavatula, S. K., Thompson, D., Ahn, S. W., Upadhyaya, K., Lammers, A., Deans, K., Dominas, C. A., Ferland, B., Valvo, V., Liu, G., et al. (2021) · Cancers · doi:10.3390/cancers13040653 · Cited by 14

The evolution of personalized medicine: literature review

Dolgopolov, I. S., & Rykov, M. Y. (2022) · Research and Practical Medicine Journal · doi:10.17709/2410-1893-2022-9-3-9 · Cited by 14

Thread as a Low-Cost Material for Microfluidic Assays on Intact Tumor Slices

Rumaner, M., Horowitz, L. F., Ovadya, A., & Folch, A. (2019) · Micromachines · doi:10.3390/mi10070481 · Cited by 13

Abstract 228: A novel device to perform rapid high-throughput in vivo drug sensitivity testing and identify optimal drug therapy for personalized cancer treatment

Jonas, O. H. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-228

Abstract 4381: High-throughput in vivo systems biology using implantable microdevices

Jonas, O. H. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4381 · Cited by 1

A Novel Device for Direct Determination of Tumor Chemotherapeutic Sensitivity

Wang, M., & Serak, J. (2015) · Neurosurgery · doi:10.1227/01.neu.0000471839.05005.18

Personalized Devices Predict Cancer Drug Sensitivity In Vivo:

Balakrishnan, V. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv267

Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.

Traina, T. A., Plitas, G., Reis-Filho, J. S., Morris, E. A., Hughes, M. C., Sung, J. S., Patil, S. N., Piscuoglio, S., Park, S., Greenberg, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps1101 · Cited by 1